Tiplaxtinin, a selective and orally efficacious inhibitor of SERPINE1, was applied to test whether SERPINE1 plays a role in DIO-mediated tumor radioresistance (Fig. S2H). The gene discussed is SERPINE1; the disease is neoplasm.